Drug Profile

Darlifarnib - Kura Oncology

Alternative Names: KO-2806

Latest Information Update: 19 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kura Oncology
Class Antineoplastics; Small molecules
Mechanism of Action Farnesyltranstransferase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

12 Aug 2026 Updated efficacy data from a phase I trial in Solid tumours released by Kura Oncology
12 Aug 2026 Kura Oncology plans a phase Ia platform trial for Adenocarcinoma (Combination therapy, Second-line therapy or greater) (PO) in first half of 2027
28 Jul 2026 Updated efficacy and adverse event data from a phase I trial in Solid tumours released by Kura Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com